The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Efficacy and safety of fedratinib in patients with myelofibrosis and low platelet counts
Francesco Passamonti, MD, University of Milan, Milan, Italy, comments on the efficacy and safety of fedratinib in patients with myelofibrosis and low baseline platelet counts, highlighting the results of the FREEDOM2 trial (NCT03952039). The findings of this trial show that the efficacy of fedratinib was similar in patients with high and low platelet counts, and fedratinib was associated with an increase in platelet count compared to the control arm. This shows that fedratinib is a suitable treatment choice for patients with low platelet counts. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
This is another important study. The focus is the second line treatment of patients with myelofibrosis. So patients who fail ruxolitinib in the first line, and proceed to fedratinib. And here we report the result of the FREEDOM-2. The FREEDOM-2 is a study that in this setting of ruxo failure, compare patients receiving fedratinib versus best available therapy. And we have also already presented the data, the clinical results, the data of the clinical results at past EHA meeting and this is on the public...
This is another important study. The focus is the second line treatment of patients with myelofibrosis. So patients who fail ruxolitinib in the first line, and proceed to fedratinib. And here we report the result of the FREEDOM-2. The FREEDOM-2 is a study that in this setting of ruxo failure, compare patients receiving fedratinib versus best available therapy. And we have also already presented the data, the clinical results, the data of the clinical results at past EHA meeting and this is on the public. And for this meeting on ASH 2024, we decided to discuss the issue of platelet. And so we compare efficacy in the cohort of patients who had the platelet count 50 to 100,000 versus those with more than 100,000. And we found that the efficacy of the fedratinib is similar in these two different cohorts in terms of SVR, so means spleen volume reduction 35%, symptomatology and also an immune improvement. And you also find that those patients who receive fedratinib have an increase of platelet count from the beginning in respect to those who receive best available therapy. So what is the final message of this presentation is that we can use fedratinib in those patients with the platelet count 50 to 100,000 without any problem with a high grade of efficacy and this is quite important because this comprises the cohort of patients that is about 20 percent to 25 percent of the patients with primary myelofibrosis or secondary myelofibrosis.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Abbvie: Honoraria, Speakers Bureau; Janssen: Honoraria, Speakers Bureau; AOP: Honoraria, Speakers Bureau; GSK: Honoraria, Speakers Bureau; Karyiopharma: Honoraria, Speakers Bureau; Kyowa Kirin: Honoraria, Speakers Bureau; MEI: Honoraria, Speakers Bureau; Sumitomo: Honoraria, Speakers Bureau; BMS/Celgene: Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau; Kartos Therapeutics Inc.: Honoraria, Speakers Bureau.
